cyrilzakka/clinical-trials huggingface dataset:
Is It Possible to Predict Pre Term Labor by Measuring Cervical Length in the Non-pregnant Uterus?

Working hypothesis and aims:

To investigate the association between cervical length in non-pregnant women, and the risk of premature birth.

The participants will be recruited from the HaEmek Medical Center delivery room registration. Women delivered between 24-37 pregnancy weeks will be allocated to the study group. The investigators will invite them 3 month or more after delivery to ultrasound examination of the cervical length. The participants in the control group will be the women whom term delivery follows by chronological manner to those in study group. Data of the cervucal length will be collected at the time of the examination.

Women will be invited to undergo an examination in Ultrasound Unit of Department of Obstetrics and Gynecology, HaEmek Medical Center.

Ultrasound examination will be performed using the Voluson E8 device, General Electric.

The cervical length,between the external and internal orifice will be measured using conventional technologies available including: Doppler, three dimensional and two dimensional ultrasound.

Eligibility Criteria:
Inclusion Criteria:

* Nonpregnant women aged 18-40 years.
* Singelton last pregnancy.
* Last birth, spontaneous premature (24-37 week)
* Last birth at least 3 months ago.

Exclusion Criteria:

* Presence of uterine malformations.
* Sonographic pathologic findings.
* Technical failure (failed appropiate sonographic visualisation)
* Presence of fetal malformations ( in preterm delivery )
* Presence of comorbidities including diabetes, hypertension, collagen disease, thrombophilia
* Presence of risk factors for premature delivery (amniotic fluid infection,

  * cervical surgical treatments - conization, polyhydramnios, etc.).
Comparative Effects of Myofascial Induction Therapy Versus Gastrocnemius Pressure Release Treatment on Trigger Point Pressure Pain Threshold in Proximal Muscles and Ankle Range of Motion.

The aim of the study is to test the effect of myofascial induction and pre-pressure release of the grastrocnemius muscle on the proximal musculature: biceps femoris, flexor digitorum brevis and extensor digitorum grandus on the pain pre-pressure threshold variable and range of motion of ankle with knee bend and flexed


Eligibility Criteria:
Inclusion Criteria:

* Subjects from 18 to 39 years old.
* Healthy subjects with trigger point 1 of the gastrocnemius muscle in both lower limbs

Exclusion Criteria:

* Diagnosis of lower limb injury, including any tendinopathy, bursitis, ligamentous involvement, and/or fasciitis
* History of lower limb surgery or history of lower-extremity injury with residual symptoms (pain or feeling of sensations) within the last year.
* Participants could not have undergone ankle stretching or any other treatment.
* Diabetes due to possible alteration of arterial distal circulation.
* Foot deformity, cavus, and flat feet.
* Foot deformities, such as hammer toes and hallux valgus,
* Plantar corns and calluses.
* Lower limb dysfunction or chronic injury.
Performance of QDOT Micro™ Catheter With nGEN Generator for Patients With AFIB.

This workflow study will further evaluate the acute performance and safety of the QDOT MICRO™ catheter in a clinical setting used in combination with nGEN Generator. Subjects will be followed for 7 days post procedure.


Eligibility Criteria:
Inclusion Criteria:

1. Subjects diagnosed with symptomatic paroxysmal or early persistent AF undergoing a catheter ablation procedure through pulmonary vein isolation.
2. Age 18 or older.
3. Signed the Patient Informed Consent Form (ICF).

Exclusion Criteria:

1. If the patient has had a ventriculotomy or atriotomy within the preceding twelve weeks.
2. Presence of a myxoma or an intracardiac thrombus.
3. Presence of prosthetic valves.
4. Presence of active systemic infection
5. Patient with an interatrial baffle or patch
6. Women who are pregnant (as evidenced by pregnancy test if pre-menopausal), lactating, or who are of child bearing age and plan on becoming pregnant during the course of the clinical investigation.
Levosimendan Versus Dobutamine in Cardiopatic Patients Undergoing Major Non Cardiac Surgery

This study wants to investigate the hemodynamic changes in cardiopatic patients undergoing major non cardiac surgery, during and after the continuous infusion of levosimendan or dobutamine.


Eligibility Criteria:
Inclusion Criteria:

* EF \< 40%, no liver and renal disfynction, chronic cardiopathy

Exclusion Criteria:

* acute coronary syndrome, life expectation \<30 days, hemodialysis, ventricular tachycardia/ventricular fibrillation
Pupillometry in Delayed Sleep Wake Phase Disorder

The goal of this observational study is to characterize the pupil light response in patients with delayed sleep-wake phase disorder. A subset of participants will take part in a clinical trial to determine if increasing serotonin can alter the circadian response to light. The main questions it aims to answer is:

Are there differences in the light response in patients with delayed sleep-wake phase disorder? Does citalopram increase melatonin suppression in patients with delayed sleep-wake phase disorder?

Participants will complete activity and melatonin testing at home to determine their circadian timing. This will be followed by an eye test looking at the pupil response to different light stimuli. A subset of participants will complete two inpatient admissions where melatonin levels will be sampled and they will be exposed to a bright light. During one round of testing they will receive a placebo and in the other round of testing they will take a single dose of citalopram, a selective serotonin reuptake inhibitor.


Eligibility Criteria:
Inclusion Criteria:

* Delayed sleep-wake phase disorder

Exclusion Criteria:

* Use of medications known to alter pupil diameter
* History of eye disease or eye surgery
* Unstable medical or psychiatric condition
* Shift work or self imposed irregular sleep schedules
* Caffeine consumption \>400mg/day
Bispectral Index and End-Tidal Anesthetic Gas Concentration in Pediatric Patients

The purpose of this study is to investigate the relationship between BIS™ values including EEG profile and anesthetic agents in the pediatric population

This is a multi-center, prospective, observational, non-invasive, randomized controlled study to collect data to compare the performance of standard practice (SP) group with the BIS™ monitoring (BIS) group. Pediatric patients between the ages of 4 to 18 years undergoing routine sevoflurane general anesthesia with an expected surgical procedure duration of greater than 30 minutes will be recruited. If the surgery is less than 15 minutes, the data will continue to be collected, but will not be included in the data analysis and the subject will be replaced with an additional subject. General surgeries including abdominal, urological, orthopedic, or ophthalmological procedures with an American Society of Anesthesiologists physical status of I - III.

Eligibility Criteria:
Inclusion Criteria:

* Pediatric Subjects (ASA physical status I or II or III) aged: 4 years to 18 years scheduled for procedures with sedation where the process of assessment will not interfere with the procedure, progress, or patient care

Exclusion Criteria:

* Has severe contact allergies that may cause a reaction to standard adhesive materials found in pulse oximetry sensors, ECG electrodes, respiration monitor electrodes, or other medical sensors
* Known neurological disorder (e.g., epilepsy, the presence of a brain tumor, a history of brain surgery, hydrocephalic disorders, depression needing treatment with anti-depressive drugs, a history of brain trauma, hemiplegia, demyelinating disorders, cerebral palsy, congenital anomalies of the brain or spinal cord, or other known neurologic disorders)
* Severe developmental delay per assessment of investigator or report of parent/guardian
* Airway abnormalities
* Pregnancy; subjects of childbearing potential will have a urine screen for pregnancy before surgery
* If the process of assessment will interfere with the procedure or the progress of the procedure
* Taking psychoactive medications
* Taking any medications that may have an impact on the Central Nervous System (CNS)
* Planned use of any regional anesthesia; a local field block is not included in this exclusion and can be used at the discretion of the anesthesia provider
Pharmacokinetics and Toxicodynamics of Daptomycin in Bone and Joint Infections

the aim of this study is to investigate the relationship between exposure to daptomycin and the occurrence of muscle toxicity or eosinophilic pneumonia in patients treated with daptomycin for bone and joint infection

Daptomycin is widely used in osteoarticular infections (IOA), as an alternative to vancomycin, and recommended for this use by various learned societies including the Infectious Diseases Society of America (IDSA) in 2013.

Tolerance to daptomycin is generally favorable, with in particular better renal tolerance than vancomycin. However, two rare and potentially severe side effects have been described with this antibiotics: muscle toxicity and eosinophilic pneumonia.

Eligibility Criteria:
Inclusion Criteria:

* Patients who have had an osteoarticular infection, treated with daptomycin, with at least one blood test for daptomycin performed

Exclusion Criteria:

* Patients who objected to participating in the study
* Absence of blood dosage of daptomycin
A Treatment IND for 566C80 Therapy of Pneumocystis Carinii Pneumonia

To facilitate provision of atovaquone (566C80) to patients who have mild to moderate Pneumocystis carinii pneumonia (PCP) and are intolerant and/or unresponsive to trimethoprim / sulfamethoxazole (TMP / SMX ); to monitor serious adverse events attributable to 566C80.


Eligibility Criteria:
Inclusion Criteria

Patients must have the following:

* Clinical diagnosis of acute mild to moderate Pneumocystis carinii pneumonia.
* Dose-limiting intolerance to TMP / SMX or inadequate response to TMP / SMX.
* Willingness and ability to give informed consent. The clinical condition of the patient and appropriate physiologic criteria should be used in evaluating patients for therapy with 566C80. Patients who are rapidly progressing in disease severity or have severe disease as evidenced by sustained tachypnea (e.g., sustained respiratory rate \> 30 breaths/minute), rapid deterioration in (A-a)DO2 and chest radiograph may not be appropriate candidates for oral therapy, including 566C80. Therapy with parenteral pentamidine should be undertaken in these cases. Treatment with IV trimetrexate or primaquine / clindamycin should be considered for these patients unless the patient is known to have dose-limiting intolerance to these agents. Patients with severe PCP who are intolerant and/or unresponsive to therapy with TMP / SMX and parenteral pentamidine may enroll in the 566C80 open-label compassionate plea protocol.

Exclusion Criteria

Patients with the following prior conditions are excluded: History of serious or dose-limiting adverse experience during previous 566C80 therapy, thought to be attributable to the drug.
Use of a Bearable Continuous Interstitial Glucose Monitoring Device (GuardianR) During Teaching Sessions to Functional Insulin Therapy Concept in Patients Suffering From Type 1 Diabetes: Evaluation at 6 and 12 Months

The objective of the project is to evaluate advantages from the use of a bearable continuous interstitial glucose monitoring device (GuardianR) during educative sessions of diabetic patients dedicated to functional insulin therapy teaching. This concept of intensified treatment is based on testing and explanation of simplified decision making algorithms to adapt insulin dose to every true life conditions. As self monitoring of capillary glucose level is needed to validate those algorithms, we postulate that using a device able to permanently control interstitial glucose readable by both medical team and patient himself (during the session and the 5 following days after discharge) could significantly improve safety and efficiency of such educative session.

Two groups of 60 patients (experimental and control groups) will be followed and evaluated at 6 and 12 months. We do think that this new tool would facilitate education of patients and lead further to a better glycemic control.

Eligibility Criteria:
Inclusion Criteria:

* Subject major, from 18 to 70 years old
* Diabetes of type 1 defined according to the criteria of American Diabetes Association
* Insulinic treatment for at least 12 months
* Understood HbA1C enters 6,5 and 9,5 %

Exclusion Criteria:

* Minor subjects or under guardianship
* Unbalance kétosis current or recent
* Pregnancy
* Incapacitated to participate weekly complete educational in the functional insulin-therapy,
* Evolutionary severe general disease
* Psychiatric confusions
* Unbalance chronic (HbA1c \> 9,5 %) connected to an absence of adapted coverage or to abnormal behaviors
* Pathology making not interpretable the rate of HbA1c (hemoglobinopathy, anemia)
In-situ Cytokines Expression in the CNS in Amyotrophic Lateral Sclerosis (ALS)

The investigators aim at exploring the differential/topographical in-situ expression of cytokines in the central nervous system (CNS) of patients who died with amyotrophic lateral sclerosis (ALS), using archived histopathology slides and residual paraffin blocks from autopsied cases. Previous studies from the investigators and other groups showed that inflammatory cytokines are implicated in several neurological affections, particularly neurodegenerative conditions. However, in-situ cytokine expression has never been studied so far in ALS. The investigators wanted to see if these neuro-mediators are involved in the neuromolecular chain/cascade underlying ALS.


Eligibility Criteria:
Inclusion Criteria:

* patients who died with amyotrophic lateral sclerosis, having been autopsied.

Exclusion Criteria:

* N/A
Shanghai Epidemiology Study for Adolescents and Children with Cancer

The purpose of this study is to describe the morbidity, mortality, disability and survival rate in Shanghai adolescents and children with cancer diagnosed since January 2002.

The investigators collected information of all the adolescents and children diagnosed cancer in Shanghai since January 2002, including their name, gender, the date of birth, the diagnosis date, disease diagnosis, residence address and the last follow-up time status (survival/death). The type of cancer included all malignant tumors such as Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, central nervous system tumors, Neuroblastoma, Wilms tumor and so on. Then the investigators would analyze the morbidity, mortality, disability and survival rate.

Eligibility Criteria:
Inclusion Criteria:

* 0-19 year-old children and adolescents.
* Diagnosed cancer in Shanghai since January 2002.

Exclusion Criteria:

* Patients who were lost of follow-up.
* Patient's death wasn't caused by cancer or complications but by other accidents such as car accident, fell from a great height and so on.
Latest Imaging SPECT System Evaluation Phase 1

Monocentric study for the evaluation of a whole body CZT scintigraphy system.

Monocentric evaluation of performances and clinical interest of a whole body scintigraphic acquisition system with CZT digital detectors. Comparison of image quality and resolution of the new system compared to a reference one, on phantoms and during the acquisition of a wide variety of examinations.

Eligibility Criteria:
Inclusion Criteria:

* Patients referred to our Nuclear Medicine department for bone, cardiac, pulmonary, thyroid, parathyroid, renal or cerebral perfusion scintigraphy or to DaTSCAN.

Exclusion Criteria:

* Under 18 years old patients.
* Pregnant women or at risk of pregnancy.
* Patients under guardianship
* Painful patient (EVA\>4)
* Patients in whom a standard examination is not feasible (agitation).
Temozolomide as Maintenance Therapy in Small Cell Lung Cancer

Temozolomide, a nonclassic oral alkylating agent, may delay progression in sequence with chemotherapy. This phase II trial was designed to evaluate the role of Temozolomide following 4 or 6 cycles of first-line treatment in patients with newly diagnosed SCLC.

Subjects will receive standard of care treatment for SCLC with added treatment of maintenance temozolomide. Efficacy and safety of temozolomide and one year survival and time to progression of patients will be recorded.

Eligibility Criteria:
Inclusion Criteria:

* Cytologically and/or histologically confirmed small-cell lung cancer with extensive-stage disease
* Patients must have measurable disease, this can include brain metastases
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1
* Adequate bone marrow function, as defined by: absolute neutrophil count (ANC) \>1,500/µL; platelets \>100,000/µL; hemoglobin \>=9.0 g/dL
* Normal organ function, defined as follows: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \<=2.5 × the upper limit of normal (ULN), or AST and ALT \<=5 × the ULN if liver function abnormalities are due to underlying malignancy; total serum bilirubin \<=1.5 × the ULN; serum creatinine \<=1.5 × the ULN
* Women of childbearing potential and men with partners of childbearing potential must agree to use a form of birth control that is acceptable to their physician to prevent pregnancy during treatment
* Patients must be informed of the investigational nature of this study and sign an informed consent form

Exclusion Criteria:

* Patients who are pregnant or breastfeeding
* Patients receiving other investigational agents
* Patients with leptomeningeal involvement
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements
* Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition or HIV-positive patients on combination antiretroviral therapy. However, HIV testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is necessary because these patients are at increased risk of lethal infections when treated with marrow- suppressive therapy. Excluding patients on HAART is necessary due to the potential for pharmacokinetic interactions with temozolomide.
A Multicenter Prospective Study of Application of Platelet Mapping in Acute-on-chronic-liver Failure in China

Ineffective hemostasis or a paradoxical prothrombotic state of Acute-on-chronic liver disease (ACLF) has been well established. Thrombelastography measures the dynamics of thrombin production and provides a global assessment of coagulation incorporating the cumulative effect of the interactions at various levels between plasma components and cellular component of coagulation. And through the platelet mapping, it can help provide a picture of patients' function of platelet. Based on the primary result of our derivation cohort(NCT03281278), ACLF patients with high ADP inhibition rate had high 28-day mortality.This multicenter validation cohort aims to validate the predictive role of platelet mapping in ACLF prognosis, organ failure developments and short term mortality.


Eligibility Criteria:
Inclusion Criteria:

* INR≥1.5 and total bilirubin≥85μmol/L

Exclusion Criteria:

* INR≤1.5 or total bilirubin≤85μmol/L;
* those who had hepatocellular carcinoma or other types of malignancies;
* obstructive biliary diseases or other disease lead to bilirubin evaluation;
* those who had acute hemorrhage one week before admission
* those who received platelet, cryo transfusion or plasmapheresis one week before admission
* pregnancy and breastfeeding
* those who received liver transplantation or kidney transplantation;
* combine with other disease lead to organ failure including heart failure (NYHA IV),respiratory failure（PaO2\<60mmHg),renal insufficiency(CKD 5) and conscious disturbance (GCS\<8)
* readmission;
* death within 24 hours.
MERTK Signalling in Monocytes/Macrophages in Patients With Liver Disease

This study is to investigate MER receptor tyrosine kinase (MERTK) signalling cascade on monocytes and tissue macrophages in respect to innate immune function of the cells in patients with cirrhosis at different stages of disease (Child A, B, C, acute decompensation, acute-on-chronic liver failure (ACLF)) and in comparison to patients with acute liver failure and to healthy controls.

MER receptor tyrosine kinase (MERTK) signalling cascade becomes activated on monocytes/macrophages during disease progression of liver cirrhosis from Child Pugh A to B/C, corresponding to early stages of decompensation, and before the receptor expression is increased. Factors involved in activation of the MERTK signalling cascade might be microbial products such as bacterial deoxyribonucleic acid (DNA) and other toll-like receptor (TLR)-ligands, MERTK ligands and cytokines, as shown elevated in cirrhotic patients.

Given the observation that MERTK levels peak on the day of admission with organ failure and decrease in patients surviving the episode of acute-on-chronic liver failure (ACLF), MERTK Inhibition at a time during progression of cirrhosis but before manifestation of acute decompensation with no cirrhosis (AD) or ACLF might prevent infectious complications, decompensation and improve survival in patients with cirrhosis.

This study is to investigate MER receptor tyrosine kinase (MERTK) signalling cascade on monocytes and tissue macrophages in respect to innate immune function of the cells in patients with cirrhosis at different stages of disease (Child A, B, C, acute decompensation, acute-on-chronic liver failure (ACLF)) and in comparison to patients with acute liver failure and to healthy controls.

Eligibility Criteria:
Inclusion Criteria:

* Patients with compensated or decompensated chronic liver disease
* Patients with acute- or acute-on-chronic chronic liver failure
* Controls with no liver disease

Exclusion Criteria:

* Evidence of disseminated malignancy
Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin with Metformin

Phase 3 study to assess the Efficacy and Safety of CT-L03-301 in Type 2 Diabetes Patients with Insufficient Glycemic Control with Metformin and Empagliflozin Combination Therapy.


Eligibility Criteria:
Inclusion Criteria:

* Adults at the time of signing the Informed Consent Form (ICF)
* Signed the written ICF voluntarily after being fully informed of the objectives, methods, and effects of the study
* Diagnosed with T2DM

Exclusion Criteria:

* Diagnosed with other types of diabetes than T2DM
* History of hypersensitivity reaction to the components or drugs of the same class as the IP or the background therapy
* Uncontrolled severe complications of diabetes